GS-441524

GS-441524
Legal status
Legal status	AU: Yes; UK: Yes; US: Investigational drug; EU: No, legal treatment available in the Netherlands;
Identifiers
	IUPAC name (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile;
CAS Number	1191237-69-0 ;
PubChem CID	44468216;
DrugBank	DB15686;
ChemSpider	28499294;
UNII	1BQK176DT6;
KEGG	C22275;
ChEBI	CHEBI:147281;
ChEMBL	ChEMBL2016757;
Chemical and physical data
Formula	C12H13N5O4
Molar mass	291.267 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N;
	InChI InChI=1S/C12H13N5O4/c13-4-12(10(20)9(19)7(3-18)21-12)8-2-1-6-11(14)15-5-16-17(6)8/h1-2,5,7,9-10,18-20H,3H2,(H2,14,15,16)/t7-,9-,10-,12+/m1/s1; Key:BRDWIEOJOWJCLU-LTGWCKQJSA-N;

GS-441524 is a nucleoside analogue antiviral drug which was developed by Gilead Sciences. It is the main plasma metabolite of the antiviral prodrug remdesivir, and has a half-life of around 24 hours in human patients. Remdesivir and GS-441524 were both found to be effective in vitro against feline coronavirus strains responsible for feline infectious peritonitis (FIP), a lethal systemic disease affecting domestic cats. Remdesivir was never tested in cats (though some vets now offer it), but GS-441524 has been found to be effective treatment for FIP.

It is widely used despite no official FDA approval due to Gilead's refusal to license this drug for veterinary use. In several countries oral GS-441524 tablets (and injectable remdesivir) became legally available to vets for the treatment of FIP in cats, for example Australia, the Netherlands, and the United Kingdom.

Besides remdesivir, other prodrugs include obeldesivir (Gilead Sciences, Phase III) and deuremidevir (Vigonvita/Junshi, conditional approval in China).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.